Citation 11535

YOSHIKAWA,M: SHIMODA,H: NISHIDA,N: TAKADA,M: MATSUDA,H:. (2002). SALACIA RETICULATA AND ITS POLYPHENOLIC CONSTITUENTS WITH LIPASE INHIBITORY AND LIPOLYTIC ACTIVITIES HAVE MILD ANTIOBESITY EFFECTS IN RATS.. 132(7)

Citation Details

Title	SALACIA RETICULATA AND ITS POLYPHENOLIC CONSTITUENTS WITH LIPASE INHIBITORY AND LIPOLYTIC ACTIVITIES HAVE MILD ANTIOBESITY EFFECTS IN RATS.
Authors	YOSHIKAWA,M: SHIMODA,H: NISHIDA,N: TAKADA,M: MATSUDA,H:
Year	2002
Volume	132
Issue	7

Summary

Year: 2002

Journal: Unknown

Organisms and Their Experiments (1)

Salacia reticulata (HIPPOCRATEACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF EXTRACT - IN VITRO	None	ACTIVE
2	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF EXTRACT - IN VITRO	None	ACTIVE
3	LIPOLYTIC EFFECT	PHARMACOLOGY OF EXTRACT - IN VITRO	None	INACTIVE
4	ALPHA-GLYCEROLPHOSPHATE DEHYDROGENASE INHIBITION	PHARMACOLOGY OF EXTRACT - IN VITRO	None	ACTIVE
5	ALPHA-GLYCEROLPHOSPHATE DEHYDROGENASE INHIBITION	PHARMACOLOGY OF EXTRACT - IN VITRO	None	ACTIVE
6	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	MANGIFERIN	None
7	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MANGIFERIN	INACTIVE
8	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	MANGIFERIN	INACTIVE
9	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	MANGIFERIN	ACTIVE
10	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	CATECHIN,EPI: (-):	None
11	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
12	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	ACTIVE
13	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
14	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	GALLOCATECHIN,EPI: (-):	None
15	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	ACTIVE
16	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	ACTIVE
17	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	INACTIVE
18	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	GALLOCATECHIN,EPI: 4'-O-METHYL: (-):	None
19	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: 4'-O-METHYL: (-):	ACTIVE
20	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: 4'-O-METHYL: (-):	ACTIVE
21	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: 4'-O-METHYL: (-):	ACTIVE
22	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	AFZELECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI: (-):	None
23	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI: (-):	ACTIVE
24	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI: (-):	INACTIVE
25	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI: (-):	INACTIVE
26	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	CATECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI:	None
27	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI:	ACTIVE
28	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI:	ACTIVE
29	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN(4-BETA-8)-(-)-4'-O-METHYL-EPI-GALLOCATECHIN,EPI:	INACTIVE
30	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	FERRUGINOL,19-HYDROXY:	None
31	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FERRUGINOL,19-HYDROXY:	ACTIVE
32	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	FERRUGINOL,19-HYDROXY:	INACTIVE
33	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	FERRUGINOL,19-HYDROXY:	INACTIVE
34	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	LAMBERTIC ACID	None
35	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LAMBERTIC ACID	ACTIVE
36	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	LAMBERTIC ACID	ACTIVE
37	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	LAMBERTIC ACID	INACTIVE
38	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	KOTALAGENIN-16-ACETATE	None
39	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KOTALAGENIN-16-ACETATE	ACTIVE
40	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	KOTALAGENIN-16-ACETATE	INACTIVE
41	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	KOTALAGENIN-16-ACETATE	INACTIVE
42	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	FRIEDELANE-1-3-DIONE,26-HYDROXY:	None
43	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FRIEDELANE-1-3-DIONE,26-HYDROXY:	ACTIVE
44	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	FRIEDELANE-1-3-DIONE,26-HYDROXY:	INACTIVE
45	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	FRIEDELANE-1-3-DIONE,26-HYDROXY:	INACTIVE
46	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	MAYTENFOLIC ACID	None
47	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MAYTENFOLIC ACID	INACTIVE
48	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	MAYTENFOLIC ACID	INACTIVE
49	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	MAYTENFOLIC ACID	ACTIVE
50	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	OLEAN-12-EN-29-OIC ACID,3-BETA-22-BETA-DIHYDROXY:	None
51	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-BETA-22-BETA-DIHYDROXY:	INACTIVE
52	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-BETA-22-BETA-DIHYDROXY:	ACTIVE
53	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-BETA-22-BETA-DIHYDROXY:	INACTIVE
54	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SALACINOL	None
55	LIPASE(PANCREATIC) INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SALACINOL	ACTIVE
56	LIPOPROTEIN LIPASE INHIBITION(ADIPOSE)	PHARMACOLOGY OF COMPOUND - IN VITRO	SALACINOL	INACTIVE
57	LIPOLYTIC EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	SALACINOL	INACTIVE

Citation 11535

Citation Details

Summary

Organisms and Their Experiments (1)

Salacia reticulata (HIPPOCRATEACEAE)

Show SPARQL Queries (1)

Query 1